[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2369 Introduced in House (IH)]







106th CONGRESS
  1st Session
                                H. R. 2369

To amend title XVIII of the Social Security Act to provide for Medicare 
coverage of certain biologicals used in treating lower extremity ulcers 
                       in patients with diabetes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 29, 1999

 Mr. Nethercutt (for himself and Mr. LaFalce) introduced the following 
bill; which was referred to the Committee on Commerce, and in addition 
  to the Committee on Ways and Means, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
To amend title XVIII of the Social Security Act to provide for Medicare 
coverage of certain biologicals used in treating lower extremity ulcers 
                       in patients with diabetes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Diabetic Foot Ulcer Care 
Improvement and Savings Act of 1999''.

SEC. 2. MEDICARE COVERAGE OF CERTAIN BIOLOGICALS USED IN TREATING LOWER 
              EXTREMITY ULCERS IN PATIENTS WITH DIABETES.

    (a) In General.--Section 1861(s)(2) of the Social Security Act (42 
U.S.C. 1395x(s)(2)) is amended--
            (1) by striking ``and'' at the end of subparagraph (S);
            (2) by striking the period at the end of subparagraph (T) 
        and inserting ``; and''; and
            (3) by inserting after subparagraph (T) the following new 
        subparagraph:
                    ``(U) recombinant human growth factor (which is 
                approved by the Food and Drug Administration) 
                prescribed for use in the treatment of a lower 
                extremity neuropathic ulcer in an individual with 
                diabetes;''.
    (b) Effective Date.--The amendments made by subsection (a) apply to 
items furnished on or after October 1, 1999.
                                 <all>